CV Sciences (CVSI) Free Cash Flow Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Free Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -79.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.04% |
| Mar 31, 2026 | -53.50% |
| Dec 31, 2025 | -51.42% |
| Sep 30, 2025 | 16.63% |
| Jun 30, 2025 | 30.13% |
| Mar 31, 2025 | 31.65% |
| Dec 31, 2024 | 46.13% |
| Sep 30, 2024 | 57.31% |
| Jun 30, 2024 | 73.50% |
| Mar 31, 2024 | 33.02% |
| Dec 31, 2023 | 63.19% |
| Sep 30, 2023 | 76.48% |
| Jun 30, 2023 | 35.65% |
| Mar 31, 2023 | 36.65% |
| Dec 31, 2022 | 26.75% |
| Sep 30, 2022 | 18.99% |
| Jun 30, 2022 | -34.66% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | -38.71% |
| Sep 30, 2021 | -32.84% |